Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine for Persistent OAB Symptoms After Bladder Outlet Obstruction Treatment
NCT00605319Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fesoterodine in overactive bladder (OAB), sponsored by Weill Cornell Medicine. Primary endpoints: International Prostate Symptom Score Obstructive Subscore at 7 months, International Prostate Symptom Score Irritative Subscore at 7 months and 5 more. Started Jan 2010; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00605319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605319.